skip to main content

Rheumatoid arthritis with persistent knee synovitis — SCE Rheumatology MCQ

Instant feedback + full explanation. One question, done properly.

ModerateInjectionsRheumatoid arthritis with persistent knee synovitisSCE Rheumatology

A 67-year-old man with anti-CCP-positive rheumatoid arthritis takes methotrexate and etanercept. His systemic disease is in low disease activity, but he has developed a symptomatic right-knee effusion with ultrasound-confirmed synovitis. There is no fever, overlying infection or recent trauma, and his CRP is unchanged from baseline. The knee has no prosthesis. He takes apixaban 5 mg twice daily for persistent atrial fibrillation and a previous transient ischaemic attack. His creatinine clearance is 78 mL/min, platelet count is 245 × 10^9/L and liver biochemistry is normal. He has no previous major bleeding. Aspiration followed by intra-articular glucocorticoid injection is planned. Which is the most appropriate periprocedural management plan?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: A — Continue apixaban without interruption and perform the aspiration and injection using standard haemostatic precautions

Explanation lettering: B = shown as A · C = shown as B · A = shown as C · E = shown as D · D = shown as E

Peripheral joint aspiration and intra-articular injection are low-bleeding-risk procedures. EULAR advises that intra-articular therapy is not contraindicated in patients taking antithrombotic medication unless the individual bleeding risk is high. Observational evidence cited by EULAR estimated a periprocedural bleeding risk of 0–2%, including no reported bleeding in 1,050 procedures performed in patients taking direct oral anticoagulants. More recent prospective evidence also supports uninterrupted DOAC therapy during ultrasound-guided intra- or periarticular procedures. This patient has normal renal, hepatic and platelet parameters, no bleeding history and a substantial thromboembolic indication for anticoagulation. Apixaban should therefore continue, with careful technique and local pressure after the procedure. A is unnecessary because anti-Xa testing is not required for this low-risk procedure. C exposes him to avoidable interruption without a demonstrated safety benefit. D is inappropriate because bridging adds bleeding risk and is unnecessary for a procedure that does not require DOAC interruption. E overlooks an appropriate local treatment for isolated synovitis when systemic rheumatoid arthritis activity is otherwise controlled; systemic escalation should not substitute for indicated aspiration, particularly when aspiration also helps reassess the cause of an effusion.

Reference: EULAR recommendations for intra-articular therapies (2021) — https://ard.bmj.com/content/80/10/1299 To stop or not to stop novel oral anticoagulants prior to performing joint interventional maneuvers? Evidence from a prospective study that the therapy can be maintained (2024) — https://pubmed.ncbi.nlm.nih.gov/39008221/